| 144653-84-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• CAS: 144653-84-9
• 化学式: C₃₀H₅₁O₃P
• 分子量: 490.707
• InChiKey: DYNURUIBRSPYSR-SBEKHEBASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.25
• 重原子数：
  34.0
• 可旋转键数：
  18.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  35.53
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  在 吡啶 、 水 、 碘 作用下， 以 四氢呋喃 为溶剂， 生成 di-farnesyl hydrogen phosphate
  参考文献：
  名称：

  Sodium di-polyprenyl phosphates form “primitive” membranes

  摘要：

  The bis phosphoric esters of dimethylallyl alcohol, isopentenol, geraniol, farnesol and geranylgeraniol have been prepared through the phosphites in order to evalUate their phase properties in water. The sodium and calcium salts of the first two are soluble in water; the others easily form closed vesicles. These could be representative of "primitive" biomcmbranes.

  DOI：

  10.1016/s0040-4039(00)79146-5
• 作为产物：
  描述：

  在 碳酸氢钠 作用下， 以 乙醚 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Birault, Veronique; Pozzi, Gianluca; Plobeck, Niklas, Chemistry - A European Journal, 1996, vol. 2, # 7, p. 789 - 799

  摘要：

  DOI：

文献信息

• AMINOGLYCOSIDE DERIVATIVES AND NANO-ASSEMBLIES THEREOF, INCLUDING THOSE WITH QUORUM SENSING INHIBITORY FUNCTION
  申请人：Helmholtz-Zentrum für Infektionsforschung GmbH

  公开号：EP3421050A1

  公开（公告）日：2019-01-02

  The present invention relates to conjugates of aminoglycosides and terpenoids, in particular sesquiterpenoids. Furthermore, the present invention relates to nano-assemblies formed by the inventive conjugates and to a method for producing the conjugates and/or the nano-assemblies. The present invention also relates to the inventive conjugates and nano-assemblies for use in therapy, in particular for use in the treatment of infectious diseases. Particularly preferred embodiments of the present invention relate to farnesylated aminoglycosides and nano-assemblies thereof, in which farnesol and its derivatives do not only function as carrier for the aminoglycosides but do themselves have pharmaceutical activity upon cleavage of the conjugate, in particular quorum sensing inhibitory activity.

  本发明涉及氨基糖苷类和萜类，特别是倍半萜类的共轭物。此外，本发明还涉及由本发明共轭物形成的纳米组合物，以及生产共轭物和/或纳米组合物的方法。本发明还涉及用于治疗的本发明共轭物和纳米组合物，特别是用于治疗传染性疾病的共轭物和纳米组合物。本发明特别优选的实施方案涉及法呢醇化氨基糖苷类化合物及其纳米组合物，其中法呢醇及其衍生物不仅作为氨基糖苷类化合物的载体，而且在共轭物裂解后本身也具有药物活性，特别是定量感应抑制活性。
• Treatment of neurodegenerative conditions by disruption of Rhes
  申请人：The Regents of the University of California

  公开号：US10864206B2

  公开（公告）日：2020-12-15

  The invention is directed to the treatment of tauopathic neurodegenerative conditions and the underlying processes thereof. Based on the discovery that Rhes acts as a negative regulator of normal tau clearance, the compositions and methods of the invention may be applied to inhibit Rhes and reduce pathogenic tau aggregation. Rhes may be disrupted by disrupting RAS2D gene expression or reducing the abundance of Rhes protein in neurons. Additionally, post-translational modifications of Rhes may be targeted, including the disruption of Rhes farnesylation by the administration of farnesyltransferase inhibitors.

  本发明旨在治疗牛头病性神经退行性疾病及其潜在过程。基于Rhes作为正常tau清除的负调控因子的发现，本发明的组合物和方法可用于抑制Rhes并减少致病性tau聚集。可通过干扰 RAS2D 基因的表达或减少神经元中 Rhes 蛋白的丰度来破坏 Rhes。此外，还可以针对 Rhes 的翻译后修饰，包括通过施用法尼基转移酶抑制剂来破坏 Rhes 的法尼基化。
• Modulators of toll-like receptors for the treatment of HIV
  申请人：Gilead Sciences, Inc.

  公开号：US11116774B2

  公开（公告）日：2021-09-14

  Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR7, including those of Formula II: and pharmaceutically acceptable salts thereof, useful in treating HIV infections.

  本发明提供以下方法、用途、药物方案、药物组合物和试剂盒，其中包含TLR7的调节剂，包括公式II中的化合物及其药学上可接受的盐，所述化合物在治疗HIV感染中有用。
• Isoprenoid analog compounds and methods of making and use thereof
  申请人：——

  公开号：US20030022869A1

  公开（公告）日：2003-01-30

  The invention provides compounds of formula I: 1 wherein X, R 1 , R 2 , and n have any of the values defined in the specification, and their pharmaceutically acceptable salts. The compounds are useful, for example, for blocking prenylation transferase enzymes, for probing or diagnosing protein prenylation processes, and for treating cancer in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula I, and intermediates useful for the synthesis of compounds of formula I.

  本发明提供了式 I 的化合物： 1 其中 X、R 1 , R 2 和 n 具有本说明书中定义的任何值，以及它们的药学上可接受的盐。例如，这些化合物可用于阻断前酰化转移酶、探测或诊断蛋白质前酰化过程以及治疗哺乳动物的癌症。本发明还提供了药物组合物、制备式 I 化合物的工艺以及用于合成式 I 化合物的中间体。
• Nakatani, Yoichi; Plobeck, Niklas; Eifler, Stephane, Phosphorus, Sulfur and Silicon and the Related Elements, 1993, vol. 77, # 1-4, p. 125 - 128
  作者：Nakatani, Yoichi、Plobeck, Niklas、Eifler, Stephane、Brisson, Alain、Ourisson, Guy

  DOI：——

  日期：——